Biodesix, Inc. (NASDAQ:BDSX – Free Report) – Equities researchers at HC Wainwright issued their Q2 2026 earnings estimates for Biodesix in a research note issued to investors on Monday, June 15th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Biodesix’s Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.87) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.65) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.36) EPS and FY2027 earnings at ($2.00) EPS.
Biodesix (NASDAQ:BDSX – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.32. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. The company had revenue of $25.56 million during the quarter, compared to the consensus estimate of $23.12 million.
Read Our Latest Analysis on BDSX
Biodesix Price Performance
Shares of NASDAQ BDSX opened at $15.33 on Wednesday. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 5.09. The business’s 50 day moving average price is $14.10 and its two-hundred day moving average price is $12.11. The company has a market cap of $158.82 million, a PE ratio of -3.78 and a beta of 0.59. Biodesix has a twelve month low of $5.00 and a twelve month high of $20.21.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in BDSX. Cetera Investment Advisers raised its holdings in Biodesix by 20.0% in the 1st quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock valued at $174,000 after buying an additional 2,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares during the last quarter. State Street Corp increased its position in Biodesix by 15.6% in the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after acquiring an additional 2,400 shares during the period. Walleye Capital LLC bought a new position in shares of Biodesix during the first quarter valued at $157,000. Finally, Thompson Davis & CO. Inc. bought a new position in shares of Biodesix during the first quarter valued at $170,000. Institutional investors and hedge funds own 20.96% of the company’s stock.
About Biodesix
Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.
The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.
Further Reading
- Five stocks we like better than Biodesix
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
